Profile data is unavailable for this security.
About the company
Nuvation Bio Inc. is a global biopharmaceutical company. The Company is engaged in tackling the unmet needs in oncology by developing differentiated and therapeutic candidates. Its programs include taletrectinib (ROS1 inhibitor), safusidenib (mIDH1 inhibitor), NUV-1511 (drug-drug conjugate), and NUV-868 (BET inhibitor). The Company's Taletrectinib is an oral, potent, central nervous system-active, selective, ROS1 inhibitor specifically designed for the treatment of patients with ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC). Safusidenib is a novel, oral, potent, brain penetrant, targeted inhibitor of mutant isocitrate dehydrogenase 1(mIDH1). NUV-1511, a clinical-stage drug-drug conjugate (DDC), fuses a targeting agent to a widely used chemotherapy agent. Its NUV-868 is a BD2-selective, oral, small molecule bromodomain and extra-terminal (BET) inhibitor that inhibits BRD4.
- Revenue in USD (TTM)26.75m
- Net income in USD-217.48m
- Incorporated2020
- Employees291.00
- LocationNuvation Bio Inc1500 Broadway, Suite 1401NEW YORK 10036United StatesUSA
- Phone+1 (415) 754-3517
- Fax+1 (302) 636-5454
- Websitehttps://www.nuvationbio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tango Therapeutics Inc | 66.50m | -100.52m | 1.74bn | 155.00 | -- | 8.99 | -- | 26.11 | -0.9208 | -0.9208 | 0.593 | 1.43 | 0.2364 | -- | -- | 429,038.70 | -35.74 | -- | -39.69 | -- | -- | -- | -151.15 | -283.69 | -- | -- | 0.00 | -- | 15.17 | -- | -28.07 | -- | -- | -- |
| MannKind Corp | 313.79m | 28.76m | 1.74bn | 407.00 | 61.12 | -- | 46.76 | 5.54 | 0.0926 | 0.0926 | 1.02 | -0.1451 | 0.6545 | 2.52 | 17.64 | 770,975.40 | 6.00 | -14.54 | 7.40 | -19.49 | 78.49 | 65.89 | 9.16 | -28.96 | 3.04 | 2.68 | 1.14 | -- | 43.50 | 35.27 | 331.09 | -- | 30.46 | -- |
| Galecto Inc | 0.00 | -15.84m | 1.75bn | 5.00 | -- | 5.80 | -- | -- | -12.01 | -12.01 | 0.00 | 6.03 | 0.00 | -- | -- | 0.00 | -92.89 | -47.05 | -109.09 | -50.67 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 44.10 | -- | -- | -- |
| Olema Pharmaceuticals Inc | 0.00 | -149.96m | 1.78bn | 122.00 | -- | 5.04 | -- | -- | -1.81 | -1.81 | 0.00 | 4.48 | 0.00 | -- | -- | 0.00 | -51.48 | -31.26 | -58.78 | -33.05 | -- | -- | -- | -- | -- | -- | 0.0097 | -- | -- | -- | -33.95 | -- | -- | -- |
| Syndax Pharmaceuticals Inc | 111.55m | -311.58m | 1.78bn | 270.00 | -- | 15.42 | -- | 15.96 | -3.61 | -3.61 | 1.29 | 1.33 | 0.2282 | -- | 4.67 | 413,151.80 | -63.74 | -32.19 | -77.50 | -35.11 | 95.44 | -- | -279.31 | -440.06 | 4.42 | -87.92 | 0.7487 | -- | -- | 73.25 | -52.25 | -- | -- | -- |
| Recursion Pharmaceuticals Inc | 43.69m | -715.54m | 1.81bn | 840.00 | -- | 1.64 | -- | 41.53 | -1.81 | -1.81 | 0.109 | 2.13 | 0.0411 | -- | 3.62 | 52,010.71 | -67.31 | -42.93 | -76.86 | -48.71 | -59.01 | -- | -1,637.81 | -828.92 | -- | -- | 0.0195 | -- | 32.00 | 90.93 | -41.33 | -- | 28.49 | -- |
| Stoke Therapeutics Inc | 205.63m | 40.57m | 1.82bn | 128.00 | 48.35 | 5.71 | 42.93 | 8.86 | 0.66 | 0.66 | 3.52 | 5.59 | 0.6293 | -- | 35.68 | 1,606,500.00 | 12.41 | -34.04 | 14.44 | -37.36 | -- | -- | 19.73 | -749.56 | -- | -- | 0.00 | -- | 316.34 | -- | 15.01 | -- | -34.11 | -- |
| Semnur Pharmaceuticals Inc | 0.00 | -1.46m | 1.84bn | -- | -- | -- | -- | -- | -0.4678 | -0.4678 | 0.00 | -4.05 | 0.00 | -- | -- | -- | -5.54 | -- | -7.67 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -126.45 | -- | -- | -- |
| Nuvation Bio Inc | 26.75m | -217.48m | 1.98bn | 291.00 | -- | 6.07 | -- | 73.96 | -0.6399 | -0.6399 | 0.0787 | 0.9508 | 0.0456 | -- | 6.34 | 121,581.80 | -37.08 | -33.42 | -41.58 | -34.49 | 54.26 | -- | -813.07 | -11,132.31 | 8.39 | -- | 0.3842 | -- | -- | -- | -649.24 | -- | -24.47 | -- |
| Soleno Therapeutics Inc | 98.68m | -78.45m | 2.00bn | 152.00 | -- | 4.04 | -- | 20.27 | -1.84 | -1.84 | 2.02 | 9.21 | 0.2201 | -- | -- | 1,072,554.00 | -17.50 | -59.81 | -18.49 | -66.17 | 98.14 | -- | -79.50 | -- | 15.88 | -- | 0.0915 | -- | -- | -- | -351.04 | -- | 59.68 | -- |
| Dianthus Therapeutics Inc | 3.08m | -126.35m | 2.03bn | 78.00 | -- | 3.72 | -- | 660.27 | -3.48 | -3.48 | 0.085 | 12.75 | 0.0066 | -- | 0.8013 | 39,461.54 | -27.12 | -37.13 | -28.32 | -39.78 | -- | -- | -4,104.78 | -3,874.39 | -- | -- | 0.00 | -- | 120.63 | -- | -95.08 | -- | -49.06 | -- |
| Disc Medicine Inc | 0.00 | -181.11m | 2.11bn | 84.00 | -- | 3.42 | -- | -- | -5.35 | -5.35 | 0.00 | 16.38 | 0.00 | -- | -- | 0.00 | -32.18 | -- | -33.75 | -- | -- | -- | -- | -- | -- | -- | 0.0481 | -- | -- | -- | -43.08 | -- | -- | -- |
| Mineralys Therapeutics Inc | 0.00 | -171.36m | 2.18bn | 51.00 | -- | 3.78 | -- | -- | -2.96 | -2.96 | 0.00 | 7.30 | 0.00 | -- | -- | 0.00 | -39.48 | -- | -42.14 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -147.31 | -- | -- | -- |
| Maze Therapeutics Inc | 0.00 | -101.46m | 2.21bn | 125.00 | -- | 5.83 | -- | -- | -2.68 | -2.68 | 0.00 | 7.89 | 0.00 | -- | -- | 0.00 | -41.05 | -- | -43.88 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 103.39 | -- | -- | -- |
Data as of Feb 13 2026. Currency figures normalised to Nuvation Bio Inc's reporting currency: US Dollar USD
35.38%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 30 Sep 2025 | 50.06m | 14.60% |
| BlackRock Fund Advisorsas of 30 Sep 2025 | 19.98m | 5.83% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 13.67m | 3.99% |
| Laurion Capital Management LPas of 30 Sep 2025 | 9.71m | 2.83% |
| SSgA Funds Management, Inc.as of 30 Sep 2025 | 6.09m | 1.78% |
| Geode Capital Management LLCas of 30 Sep 2025 | 5.89m | 1.72% |
| Millennium Management LLCas of 30 Sep 2025 | 4.85m | 1.42% |
| Tang Capital Management LLCas of 30 Sep 2025 | 4.20m | 1.23% |
| Abrams Capital Management LPas of 30 Sep 2025 | 3.81m | 1.11% |
| Redmile Group LLCas of 30 Sep 2025 | 3.03m | 0.88% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
